Community-acquired pneumonia (CAP) is associated with significant mortality and morbidity, and high costs globally. [1] The epidemiology of CAP demonstrates high regional and geographic variability with regard to age, risk factors, disease severity and causative pathogens. The identification of a pathogen in patients with CAP is an important, but seemingly elusive, goal. Nonetheless, clinicians should make every effort to identify a pathogen in hospitalised patients with CAP, as doing so will allow for targeted therapy. Narrow and directed therapy promotes antibiotic stewardship, which improves patient outcomes, minimises side-effects, shortens treatment duration, reduces the risk of developing complications such as Clostridium difficile infection and reduces the overall cost of care.Despite the obvious benefits of individualised therapy, the failure to identify pathogens in the majority of patients has led to an empirical treatment strategy in most parts of the world. The choice of empirical therapy varies slightly between settings, but is generally based on local epidemiology and pathogen profile, local antibiograms, the risk-profiling of patients, travel and exposure histories and disease severity. This strategy has helped to standardise treatment approaches to some degree, promotes rational selection of antibiotics and has been demonstrated to improve clinical outcomes. [2] The microbiological aetiology of CAP has been of much interest since the introduction of antibiotics for its treatment almost a century ago. In the pre-antibiotic era, Streptococcus pneumoniae caused 95% of the cases of pneumonia, but this has declined dramatically in the era of antibiotic therapy and pneumococcal vaccination. Globally, S. pneumoniae remains the most commonly identified cause of pneumonia, accounting for between 10 and 15% of hospitalised cases. However, with improved diagnostic capacity in recent years, additional pathogens have been identified, such as Haemophilus influenzae, Staphylococcus aureus, Moraxella catarrhalis, Pseudomonas aeruginosa, Mycoplasma pneumoniae, Chlamydophila pneumoniae and indeed, Mycobacterium tuberculosis. In a large population-based surveillance study of CAP in hospitalised adults, which employed systematic collection of urine, blood and respiratory specimens for culture, serological testing, antigen detection and molecular diagnostic testing, a pathogen was detected in only 38% of cases. [3] Similarly to other rigorous studies of CAP aetiology, viral pathogens somewhat surprisingly accounted for twice as many cases as bacterial pathogens, and polymicrobial infection was not uncommon. [4,5] As diagnostic capabilities improve further, we are likely to aim for a more individualised approach to the treatment of CAP. To do so, however, we must begin to characterise the local CAP epidemiology, including the profile of pathogens in our setting. Previous work by Nyamande et al. [4] revealed that systematic diagnostic investigations performed at a single centre in KwaZulu-Natal yielded a pathogen in ove...